Biocon And Viatris Scoop EU Insulin Aspart Approval
Analyst Expects Biosimilar Penetration To Be ‘Slow And Minimal’
Kixelle’s approval comes soon after Biocon announced the abrupt exit of Biocon Biologics’ CEO Christiane Hamacher • Source: Shutterstock 
